title: Prognosis of Ramsay Hunt syndrome presenting as cranial polyneuropathy.
abstract: OBJECTIVE
  Ramsay Hunt syndrome is known to be accompanied with cranial polyneuropathy very occasionally. We reviewed our experience to analyze the clinical manifestations and prognosis of these cases.
  
  
  METHODS
  Retrospective review.
  
  
  METHODS
  Eleven patients with Ramsay Hunt syndrome presenting as cranial polyneuropathy between 1999 and 2009 were included in this study retrospectively. All patients were treated with systemic steroids and antiviral agents. Assessment of recovery from facial nerve palsy (FNP) using the House-Brackmann (HB) grading system was performed, and the follow-up period was 4 to 28 months.
  
  
  RESULTS
  The patient numbers for the initial degree of FNP were five for HB grade II, one for grade III, two for grade IV, and three for grade V. The cochleovestibular nerve was involved in 10 cases, and hearing loss was observed in nine patients. Other involved cranial nerves were IX in seven cases, X in five cases, V in three cases, and III/XII in one case each. Antiviral agents and steroids were administered within 3 days after the onset of symptoms for about 1 to 2 weeks in most cases. After the treatment the degree of FNP improved to HB grade I or II in nine of 11 patients (81.8%). Symptoms of other cranial nerves also improved in most patients, whereas recovery for hearing loss showed poor results.
  
  
  CONCLUSIONS
  Ramsay Hunt syndrome associated with cranial polyneuropathy has a good prognosis for FNP and other cranial nerve palsies with a combination therapy of antiviral agents and steroids, but not for recovery of hearing loss.
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Seoul Metropolitan Government, Seoul National University, Boramae Medical Center, Seoul, South Korea.
authors.forename: Young Ho
authors.initials: YH
authors.lastname: Kim
authors.forename: Moon Young
authors.initials: MY
authors.lastname: Chang
authors.forename: Hak Hyun
authors.initials: HH
authors.lastname: Jung
authors.forename: Yong Soo
authors.initials: YS
authors.lastname: Park
authors.forename: Seung Hwan
authors.initials: SH
authors.lastname: Lee
authors.forename: Jun Ho
authors.initials: JH
authors.lastname: Lee
authors.forename: Seung-Ha
authors.initials: SH
authors.lastname: Oh
authors.forename: Sun O
authors.initials: SO
authors.lastname: Chang
authors.forename: Ja-Won
authors.initials: JW
authors.lastname: Koo
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D003389:Cranial Nerve Diseases / Q000175:diagnosis* / Q000188:drug therapy; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D016697:Herpes Zoster Oticus / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D020127:Recovery of Function; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D000998:Antiviral Agents